PeptideDB

IGF-1 LR3

Pesquisa limitada

Modified Growth Factor Analog | Muscle Growth

IGF-1 LR3 is a synthetic 83-amino acid analog of insulin-like growth factor-1 that has never been approved for human use.

Dados moleculares e de pesquisa

Meia-vida
20-30 hours
Alvos primários
igf1, mtor
Vias (pesquisa)
injectable
Armazenamento
Lyophilized: -20°C to -80°C. Reconstituted in acetic acid: 2-8°C for 1 year. Reconstituted in BAC water: use within 7 days

Overview

IGF-1 LR3 is a synthetic 83-amino acid analog of insulin-like growth factor-1 that has never been approved for human use. The N-terminal extension and R3 substitution reduce binding protein interaction, maintaining elevated free circulating levels with ~3x greater potency than native IGF-1.

Mechanism of action

Functions as a full IGF-1 receptor agonist activating PI3K/Akt/mTOR and MAPK/ERK pathways. The modifications prevent protein sequestration, maintaining elevated free circulating levels for extended anabolic effects.

Key research findings

  • Approximately 3x more potent than native IGF-1
  • Promotes muscle hypertrophy and hyperplasia in animal models
  • 15-20% lean mass gains observed in 4-week rat studies
  • Anti-catabolic effects preserve muscle during cachexia
  • 20-30 hour half-life for sustained effects

Research applications

Muscle Growth

  • Hypertrophy — 15-20% lean mass gains in 4 weeks through satellite cell activation (rat studies).
  • Anti-Catabolic — Cancer cachexia rats maintained 30% more muscle versus placebo.
  • Hyperplasia — Creates new muscle fibers via satellite cell differentiation.

Tissue Repair

  • Wound Healing — Accelerated wound healing in animal models.
  • Ligament/Tendon Recovery — Enhanced connective tissue repair.

Metabolic

  • Nutrient Partitioning — Directs nutrients toward muscle tissue.
  • Fat Loss — Enhanced lipolysis through IGF-1 pathway.

FAQ de IGF-1 LR3

Why is IGF-1 LR3 called 'long R3'?+

The N-terminal extension and R3 (arginine) substitution reduce binding to IGF binding proteins, allowing the peptide to circulate freely for 20-30 hours instead of being sequestered. This gives it approximately 3x greater potency and systemic presence than native IGF-1.

Can I take IGF-1 LR3 with HGH?+

Not recommended. Both are IGF-1 pathway agonists, and combining them creates excessive IGF-1 levels with amplified side effects including severe hypoglycemia, joint pain, organ enlargement risk, and carpal tunnel symptoms.

How long can I safely use IGF-1 LR3?+

Maximum recommended cycle is 4-6 weeks with equal off-time. Prolonged use risks receptor desensitization, excessive organ growth, and cumulative hypoglycemia danger. Most users run 4-6 week cycles with 4-6 weeks off between.

What happens if my blood sugar drops dangerously low on IGF-1 LR3?+

Severe hypoglycemia from IGF-1 LR3 can last 20-30 hours due to the long half-life. Consume 30-60g fast carbs immediately after injection and keep glucose tablets handy. Never inject before sleep. Consider having glucagon available for emergency hypoglycemia.

References

  1. [1]Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated ratsBiochemical Journal
  2. [2]Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated isletsAmerican Journal of Physiology - Regulatory, Integrative and Comparative Physiology
  3. [3]Insulin-like growth factor I preserves host lean tissue mass in cancer cachexiaAmerican Journal of Physiology
  4. [4]Circulating Insulin-like Growth Factor-I Concentrations and Risk of 30 Cancers: Prospective Analyses in UK BiobankCancer Research
  5. [5]Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD miceAlzheimer's & Dementia
  6. [6]IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheepAmerican Journal of Physiology

Peptídeos relacionados